Gender medicine and different prevalence in asthma by reports on anti-IgE (omalizumab) treatments

Le résumé fourni par la source

Background: Generally, pathogenesis and prevalence of bronchial asthma indicates that age and sex are the major risk factors. Detailed physiological mechanisms of the changing sex ratio are not fully known. We investigated the influence of gender in anti-IgE treated asthmatics. Methods: We pooled data from ten published studies from 1999 with more of our data of severe persistent asthmatics treated with omalizumab (anti-IgE) monoclonal antibody. Static analysis was used to find gender risk factors as the ratio of treatment effect (omalizumab : control) on standardized exacerbation rate per year. Results: The studies included 3270 omalizumab treated patients, whose had severe persistent asthma according to Global Initiative for Asthma (GINA) classification. Analysis of two groups male vs female showed that the efficacy of omalizumab on asthma exacerbations was unaffected by patient age, gender, baseline serum IgE (split by median) or by 2- or 4-weekly dosing schedule, although a more large number of women were treated (1921/1349; 59 % women vs 41% men; p Conclusions: These results suggest that in population of asthmatics treated with anti-IgE the number of women is shown higher than men, it confirms that asthma should be considered with different approach by the gender for being adequately controlled on current therapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.